source
- AI bio startup Boltz secures $110 million Series A as AI drug design platform usage surgesBoltz, an artificial‑intelligence driven biotech startup, announced a $110 million Series A financing round less than a year after emerging from stealth with an initial $28 million investment. The…
- nChroma Bio halts sole clinical trial and cuts staff by halfTwo Boston-area biotech founders merged their companies a few years ago to create nChroma Bio, hoping the combined effort would weather a weak market for genetic‑medicine firms. The company has no…